An assay (test) developed at NCATS helped a research team identify a potential new drug target to treat a neurological disorder, called Charcot-Marie-Tooth disease.
Read about a screening technology that has helped researchers identify a potential new drug target for Charcot-Marie-Tooth disease, a collaboration using patient registry software, and more.
Bridging Interventional Development Gaps researchers will support two projects aimed at finding treatments for diabetic keratopathy — a condition that often leads to blindness — and severe heart attacks.
NCATS researchers will begin work on three new pre-clinical drug development projects for malaria, Lassa fever and two blood disorders through the Therapeutics for Rare and Neglected Diseases program.
How is NCATS advancing translational research? Learn more about the Center's work and some of its early successes.
MORE CENTER NEWS
Rare Diseases Clinical Research Network expands to 22 consortia and a data center.
Eleven institutions will refine 3-D human tissue chips to test the safety of drugs.
- NIH Big Data to Knowledge (BD2K) Initiative Research Education: Massive Open Online Course (MOOC) on Data Management for Biomedical Big Data (R25)
- NIH Big Data to Knowledge (BD2K) Initiative Research Education: Open Educational Resources for Sharing, Annotating and Curating Biomedical Big Data (R25)
- Publication of Notice of Proposed Rulemaking for Clinical Trials Registration and Results Submission under FDAAA
- More Funding & Notices...
- Providers' Perspectives on Male Involvement in Family Planning in the Context of a Cluster-Randomized Controlled Trial • AIDS Care
- Does Diet Matter in Multiple Sclerosis? • Multiple Sclerosis Discovery Forum
- Narrow Time Window Exists to Start HIV Therapy, Study Shows • EurekAlert!/University of Texas Health Science Center at San Antonio
- More News & Events...
IN THE SPOTLIGHT
Small Business Funding Opportunities
NCATS participates in the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs to support companies developing new therapies and diagnostics to help move bench research to clinical practice and commercialization.